Bio/Pharma Business

EC Approves Lunsumio, Roche’s Bispecific Antibody for Follicular Lymphoma

June 09, 2022

Roche has received approval from the European Commission for Lunsumio (mosunetuzumab), the first CD20xCD3 T-cell engaging bispecific antibody for treating follicular lymphoma.

Bristol Myers Squibb Acquires Turning Point Therapeutics for $4.1 Billion

June 08, 2022

The acquisition grants Bristol Myers Squibb access to the company's oncology pipeline and lead candidate, repotrectinib.

Sanofi Grants Regeneron Worldwide Exclusive License Rights to Libtayo

June 07, 2022

Sanofi will grant Regeneron worldwide exclusive license rights to Libtayo, a treatment for non-small cell lung cancer.

Astellas and GO Therapeutics Enter into Immuno-Oncology Research and License Agreement Worth Up to $783 Million

June 03, 2022

Astellas and GO Therapeutics will work together to develop novel antibodies for immuno-oncology.

Cambrex Acquires Irish Storage Company Q1 Scientific

June 03, 2022

Cambrex’s acquisition of Q1 Scientific expands the company’s storage services in the European market.

Big Pharma in the Balance

June 02, 2022

Is AI a panacea for pharma’s productivity gap?

Coming Together to Enable Cell and Gene Therapy Manufacturing

June 02, 2022

Precompetitive consortiums seek solutions to industry-wide challenges.

GSK Acquires Affinivax for $2.1 Billion

June 01, 2022

GSK’s acquisition of Affinivax will give the company access to their portfolio of next-generation pneumococcal vaccines.

Thermo Fisher Scientific and LabShares Partner to Support Emerging Boston Biotechs

May 31, 2022

Through the Thermo Fisher Scientific and LabShares Newton partnership, life science startups can accelerate early-stage discovery and development with shared lab spaces.

Lonza, IBF Collaborate to Support Development and Manufacturing of Biologics and Small Molecules

May 26, 2022

Lonza and Israel Biotech Fund form a two-year agreement to support accelerated development and manufacture of biologics and small molecules.